KERX pulled Auryxia guidance for the year after a rocky third quarter performance; Cowen’s Boris Peaker thumbs down.
Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the FDA has approved Auryxia for an additional indication. The approval is for the treatment of iron deficiency anemia in …
Cowen weighs in on encouraging ANS Phase III data expecting green light for KERX’s ferric citrate tablets.
